Eisai (OTCMKTS:ESALY) Rating Lowered to Neutral at Citigroup

Eisai (OTCMKTS:ESALY) was downgraded by research analysts at Citigroup from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Thursday, The Fly reports.

Separately, Zacks Investment Research upgraded shares of Eisai from a “sell” rating to a “hold” rating in a report on Tuesday, December 21st.

Shares of ESALY opened at $53.74 on Thursday. The company has a market cap of $15.94 billion, a price-to-earnings ratio of 26.60, a PEG ratio of 1.33 and a beta of 0.36. Eisai has a 1-year low of $53.30 and a 1-year high of $129.79. The company’s fifty day simple moving average is $61.33 and its 200 day simple moving average is $74.10. The company has a current ratio of 2.03, a quick ratio of 1.71 and a debt-to-equity ratio of 0.07.

Eisai (OTCMKTS:ESALY) last released its quarterly earnings data on Monday, November 1st. The company reported $0.13 EPS for the quarter. Eisai had a net margin of 9.00% and a return on equity of 8.50%. The firm had revenue of $1.48 billion for the quarter. As a group, research analysts forecast that Eisai will post 1.85 earnings per share for the current year.

Eisai Company Profile

Eisai Co, Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs.

Featured Article: How Do Tariffs Affect Trade Balances?

The Fly logo

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.